Dupixent (dupilumab)
Chronic Obstructive Pulmonary Disease (COPD)
Key Facts
About Regeneron
Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.
View full company profileAbout Regeneron
Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.
View full company profileAbout Regeneron
Regeneron Pharmaceuticals is a global biopharmaceutical leader with a mission to translate scientific innovation into life-changing medicines for patients with serious diseases. Founded in 1988, its achievements are anchored by blockbuster drugs like EYLEA® and Dupixent®, and a deep pipeline fueled by proprietary technologies like the VelocImmune® platform. The company's strategy combines a unique, vertically integrated R&D and manufacturing model with strategic collaborations, maintaining a fierce focus on long-term, science-driven growth.
View full company profileAbout Sanofi
Sanofi is a global biopharmaceutical leader with a mission to 'chase the miracles of science' by developing innovative medicines and vaccines. The company has strategically pivoted to become an R&D-driven, AI-powered organization, focusing its deep immunoscience expertise on high-growth areas like immunology and oncology. Its strategy is centered on accelerating drug discovery, optimizing its robust pipeline, and delivering compelling growth through breakthrough therapeutics.
View full company profileAbout Regeneron Pharmaceuticals
Regeneron is a premier biotechnology company with a mission to translate groundbreaking science into life-changing medicines for patients. Its achievements are anchored by its proprietary VelociSuite® technology platforms, which have enabled the development of a robust commercial portfolio and one of the industry's deepest pipelines. The company's strategy combines sustained internal R&D investment with selective, high-value collaborations, all supported by a fully integrated model from discovery to global commercialization.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |